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Abstract
The intestinal microbiome is emerging as a critical factor in health and disease. The microbes, although spatially restricted 
to the gut, are communicating and modulating the function of distant organs such as the brain. Stroke and other neurological 
disorders are associated with a disrupted microbiota. In turn, stroke-induced dysbiosis has a major impact on the disease 
outcome by modulating the immune response. In this review, we present current knowledge on the role of the gut microbiome 
in stroke, one of the most devastating brain disorders worldwide with very limited therapeutic options, and we discuss novel 
insights into the gut-immune-brain axis after an ischemic insult. Understanding the nature of the gut bacteria-brain crosstalk 
may lead to microbiome-based therapeutic approaches that can improve patient recovery.
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Introduction
From the moment of birth, a symbiotic relationship is estab-
lished between the host and the colonizing microbes in the 
gastrointestinal (GI) tract. These intestinal microorganisms 
regulate many aspects of the host physiology, such as metab-
olism, immune system education, and brain development 
(Sampson and Mazmanian 2015). Depletion of the micro-
biome in newborn mice results in impairment of the blood 
brain barrier, alterations in synaptic plasticity, and learning 
deficits (Sharon et al. 2016). Interestingly, all these devel-
opmental deficiencies are associated to an immature micro-
glial phenotype, suggesting a key role of the gut microbiota 
in regulating brain development via its immunomodulatory 
properties (Pronovost and Hsiao 2019). Signaling between 
the gut microbiota and peripheral organs is mediated by 
microbiome-associated molecular patterns (MAMP) and 
microbiome-secreted metabolites that can either interact 
with the mucosal epithelial and intestinal immune cells, 
stimulate the vagus nerve or reach systemic circulation 
to signal to the brain and possibly modulate neuronal and 
immune response (Schroeder and Bäckhed 2016). In turn, 
parasympathetic and sympathetic nerve fibers that innervate 
the gut wall transmit inputs from the brain to influence gut 
motility, immune cell activity, and can induce changes in the 
gut composition (Furness 2012).
Recent findings have implicated the bi-directional com-
munication between the gut and the central nervous sys-
tem (CNS) in the onset and progression of brain diseases 
(Cryan et al. 2019). A number of neurological disorders and 
brain pathologies are accompanied by an altered microbiota 
composition and reduced gut motility (Hsiao et al. 2013). 
However, mechanisms underpinning gut microbiota and host 
crosstalk remain poorly understood. In this review, we focus 
on the role of the microbiome in ischemic stroke, the most 
prevalent type that accounts for approximately 80% of all 
strokes, and we discuss recent findings that had shed light 
on the mechanisms underlying gut-immune-brain crosstalk.
Stroke Alters Microbiota Composition
The gut microbiota consists of different bacteria, viruses, 
and fungi that coexist in a synergic balance. Since the bac-
terial population in the intestine is better characterized, the 
majority of studies investigating the microbiome in health 
and disease targeted the bacterial communities. The gut 
microbiota is predominantly composed of four main bac-
terial phyla: Bacteroidetes, Firmicutes, Actinobacteria, 
and Verrucomicrobia, and disruption of the microbiota 
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homeostasis confers disease susceptibility to the host (Aru-
mugam et al. 2011).
Mounting evidences in experimental and clinical studies 
suggest that stroke alters the gut microbiota composition. 
Analysis of the gut microbiota of stroke patients revealed 
a shift in microbial composition in comparison to healthy 
individuals (Yamashiro et al. 2017) with the degree of dys-
biosis correlated with the severity of the lesion (Haak et al. 
2020; Yin et al. 2015). Similarly, the change in fecal taxo-
nomic abundance is more pronounced in mice subjected to 
a severe than a minor stroke (Singh et al. 2016). However, 
when analyzing bacterial diversity and specific bacteria 
taxa, some discrepancies are observed across clinical and 
experimental studies. Indeed, studies reported an increased 
in diversity in stool samples from stroke patients in compari-
son to asymptomatic controls (Yin et al. 2015) or no change 
in microbiota diversity between sham operated and stroke 
mice (Stanley et al. 2016). In contrary, others observed a 
reduction in diversity with depletion of certain bacteria and 
overgrowth of others in both experimental and clinical set-
tings (Yamashiro et al. 2017; Haak et al. 2020; Singh et al. 
2016) suggesting that the degree of diversity could not nec-
essarily predict for the severity of the stroke. Different stud-
ies observed an overall reduction of the Firmicutes, with a 
concomitant overgrowth of Bacteroidetes (Singh et al. 2016; 
Spychala et al. 2018). However, when analyzing microbiota 
changes at lower taxonomic ranks, there is a lack of con-
sistency regarding the specific bacterial changes in clinical 
and experimental stroke (Benakis et al. 2020a, b). Differ-
ences in the location of fecal sampling (across the GI tract 
in mice, and stool samples in patients), the methods used 
for the extraction of genomic DNA and for 16S rRNA gene 
analysis, the severity of the stroke model and the baseline 
differences in the microbiota composition (the mouse ori-
gin or inter- and intra-individual variabilities in humans) 
could be confounding factors accounting for the contradic-
tory results (Costello et al. 2009; Sadler et al. 2017; Stanley 
et al. 2018). Another confounding factor affecting the gut 
microbiota composition is the type of diet. The severe stroke 
cases are always hospitalized, where they will be treated 
with medicines and fed a hospital-controlled diet whereas 
little intervention occurs in mice after experimental stroke, 
which altogether will affect the microbiota composition in 
a different manner between rodents and humans. Overall, 
clinical and experimental data indicate a shift of the micro-
biota composition after stroke. However, to date, it is still 
not known which types of gut bacteria participate to the 
pathobiology mechanisms of stroke.
Aging alters the gut microbiota composition and is asso-
ciated with an increased inflammation and intestinal perme-
ability (Spychala et al. 2018). Following stroke, mice har-
boring an aged microbiota had higher mortality, impaired 
locomotor function, and a pro-inflammatory cytokine 
response than young mice. The stroke outcome could be 
reverted in both young and old mice by fecal microbiota 
transplantation (FMT). These experiments highlighted the 
importance of age on the microbiota state and its impact on 
disease development, and how manipulation of the micro-
biota can lead to non-invasive therapies to both prevent and 
ameliorate stroke outcome. Whereas experimental findings 
indicate a correlation with age, gut dysbiosis and stroke out-
come, the impact of other risk factors (diabetes mellitus, 
high blood cholesterol levels, alcohol consumption, high-fat 
diet, lack of exercise) and sex differences on the gut microbi-
ome and stroke outcome remains to be addressed in experi-
mental and clinical studies.
In experimental research, the mechanisms by which brain 
damage is thought to alter microbiome composition are by 
reducing gut motility mucosal barrier integrity due to post-
stroke dysregulation of the autonomous nervous system 
(ANS) (Houlden et al. 2016). Following brain injury, there 
is a loss of cholinergic activity and an increase of adrenergic 
signaling in the gut which is associated with the disruption 
of the gut barrier. Accordingly, inhibition of β-adrenergic 
activity using beta-blockers significantly restored stroke-
induced gut permeability and reduced bacterial dissemina-
tion to peripheral organs (Stanley et al. 2016). In this line, 
Singh et al. demonstrated that paralysis of the ileum alone 
can drive changes in the microbiota, arguing for a CNS-
mediated dysbiosis (Singh et al. 2016). Gut bacteria can 
sense hormones and neurotransmitters derived from the GI 
tract, and some opportunistic pathogens are able to prolifer-
ate more in the presence of the stress hormone norepineph-
rine (NE) in in vitro culture (O’Donnell et al. 2006). Inter-
estingly, following experimental stroke, there is an increased 
of NE release in the cecum, region of the gut between the 
small intestine and the colon, which could account for 
the proliferation of certain pathogens or commensal over-
growth over others (Houlden et al. 2016). In addition, the 
ANS modulates intestinal mucus secretion, and perturba-
tion of the brain to gut signals is likely to have important 
effects on the size and quality of the intestinal mucus layer. 
In this respect, Houlden et al. observed a dysregulation of 
the mucoprotein production and a decrease of the mucus-
producing goblet cells in the cecum after stroke (Houlden 
et al. 2016). Impairment of the formation of the mucus 
layer following stroke might allow commensals to come in 
direct contact with the epithelium, translocate and trigger an 
immune response, and post-stroke infection (Crapser et al. 
2016; Stanley et al. 2016; Winek et al. 2016). Also more 
data regarding the direct implication of bacterial transloca-
tion leading to infection in experimental stroke are needed 
(Oyama et al. 2018). In conclusion, brain injury triggers 
an imbalance of cholinergic and adrenergic signaling in the 
gut, increases the concentration of released NE, reduces gut 
motility and alters the gut-brain barrier which are associated 
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with microbiota dysbiosis. All these events will impact the 
gut microbial functional output and may further perturbs 
intestinal immune homeostasis.
The Gut‑Immune‑Brain Axis in Stroke
Studies using animal models have provided the strongest evi-
dence to date and have helped to elucidate the mechanisms 
underlying the gut-immune-brain interactions after stroke.
T lymphocytes are known to play a crucial role in the sec-
ondary tissue damage that follows brain injury. Pro-inflam-
matory T helper 1 cells (Th1), T helper 17 cells (Th17), 
and γδT-IL-17 + cells have been associated to contribute to 
post-stroke neurotoxicity, whereas regulatory T-cells (Treg) 
are known to exert anti-inflammatory and neuroprotective 
properties (Liesz et al. 2009; Shichita et al. 2009). There 
is a growing body of evidence supporting the key role of 
microbiota in maintaining the immune homeostasis by regu-
lating the balance between pro-inflammatory Th17 and anti-
inflammatory Treg cells in the GI tract.
Colonization of germ-free (GF) mice with post-stroke 
fecal content resulted in aggravation of the stroke outcome 
by inducing a pro-inflammatory Th1 and Th17-mediated 
response (Singh et al. 2016), suggesting that stroke-induced 
dysbiosis triggers a pro-inflammatory immune response 
which enhances brain damage. The authors demonstrated 
that T-cells coming from the Peyer’s patches invade the peri-
infarct tissue and contribute to the immune response in the 
acute phase of stroke. Moreover, restoring gut microbiota 
homoeostasis with FMT from healthy donors reduced lesion 
size and increased the number of Treg cells in the ischemic 
brain (Singh et al. 2016). However, the sole presence of 
microbiota is neuroprotective as completely eradication of 
gut bacteria in GF mice resulted in greater infarct volume 
compare to colonized mice (Singh et al. 2018). Again, this 
microbiota-mediated beneficial effect on stroke outcome 
was dependent on the lymphocyte response (Singh et al. 
2018), indicating that gut bacteria immune-modulatory role 
is essential for stroke recovery. The critical involvement of 
the gut-brain bi-directional communication in stroke was 
evidenced by showing that manipulation of the microbiota 
composition with antibiotics before the ischemic insult 
reduced the infarct volume and improved sensorimotor 
functions (Benakis et al. 2016). In this study, they showed 
that the neuroprotective effect is mediated by a microbiota-
dependent priming of intestinal dendritic cells (DC), induc-
ing an expansion of Tregs in the small intestine that act by 
suppressing the pro-inflammatory γδT-IL-17 + cells. More-
over, they identified IL-10 as a main orchestrator of Treg 
cell-mediated inhibition of γδT cell proliferation, since IL-
10 −/− mice were exempt from the protective effects. This 
anti-inflammatory environment in the gut is relayed to the 
brain since fewer pro-inflammatory IL-17 + γδT-cells accu-
mulated in the meninges, which is associated with smaller 
infarct volume. Interestingly, intestinal T-cells migrate from 
the gut to the meninges and the brain parenchyma demon-
strating a direct gut-brain communication route in stroke 
(Benakis et al. 2016; Singh et al. 2016). These studies illus-
trate that microbiota is affected after stroke and that changes 
in the bacterial population promote a pro-inflammatory 
T-cell response, migration of intestinal immune cells to the 
meninges after stroke which altogether might participate in 
secondary brain damage and worsens stroke outcome. In 
addition, modification of the gut microbiota composition 
can skew the intestinal immune response towards an anti-
inflammatory milieu via tolerogenic DC. Taken together, 
these findings highlighted a direct connection along the gut-
brain axis via intestinal lymphocytes trafficking from the gut 
to the brain where they modulate the neuroinflammatory 
response to stroke (Benakis et al. 2016; Singh et al. 2016). 
However, it is still not known whether intestinal immune 
cells contribute directly to brain injury or repair mecha-
nisms. Importantly, the molecular pathways underlying this 
gut bacteria-DC interaction remain elusive (Fig. 1).
Manipulation of the Gut Microbiota 
in Stroke
Benakis et al. demonstrated that treatment of mice with 
ampicillin or vancomycin prior inducing the ischemic insult 
confers neuroprotection, whereas mice were not protected 
from stroke when using neomycin (Benakis et al. 2020a, b). 
This neuroprotection is associated with an antibiotic-specific 
shift in the microbiome composition with an expansion of 
Proteobacteria and Firmicutes, and a reduction of Bacteroi-
detes. Moreover, when they analyzed the predictive enzy-
matic pathways associated with the beneficial microbiota 
changes, they found that xenobiotic/aromatic compound 
metabolism was predictive of the size of the ischemic lesion 
(Benakis et al. 2020a, b; Stanley et al. 2018). Microbiota-
derived metabolites are one of the main communication 
channels underlying bacteria–host crosstalk. One possible 
missing link implicated in the gut-immune-brain axis in 
stroke could be metabolites that are exclusively produced 
by bacteria.
Metabolite products of the essential aromatic amino 
acid tryptophan are known to modulate immune cell func-
tion through the aryl hydrocarbon receptor (AHR) which is 
expressed in both DC and T-cells (Lamas et al. 2018). Some 
bacteria members are capable of catabolizing tryptophan in 
the gut into ligands of AHR. In mice, activation of AHR by 
microbiota-derived indoles promotes intestinal homeostasis 
through induction of interleukin-22 in immune cells (Zelante 
et al. 2013). Activation of AHR in astrocytes by tryptophan 
 NeuroMolecular Medicine
1 3
metabolites drives neuroprotection in a mouse model of 
multiple sclerosis (Rothhammer et al. 2016). However, the 
protective effect seems to be ligand depend, as other trypto-
phan metabolites have been reported to aggravate the disease 
course (Veldhoen et al. 2008). Interestingly, the activity of 
kynurenine pathway responsible for tryptophan endogenous 
catabolism is upregulated following ischemic stroke and has 
been associated with the inflammatory response and a wors-
ened outcomes (Brouns et al. 2010). Accordingly, pharmaco-
logical and genetic blockade of the AHR receptor improved 
stroke recovery (Chen et al. 2019). These findings suggest 
a pivotal role for tryptophan-derived compounds in stroke. 
Yet the immunomodulator effect of the microbiota-derived 
tryptophan metabolites in ischemic injury remains to be 
elucidated.
Short chain fatty acids (SCFA) are bioproducts of bac-
terial fermentation with immunomodulatory roles: they 
are able to directly induce T-cell differentiation into effec-
tor and regulatory cells depending on the immune context 
(Park et al. 2015). Strikingly, levels of plasma SCFA were 
significantly reduced after stroke in mice, and this was asso-
ciated with a worsened outcome (Sadler et al. 2020). SCFA 
Fig. 1  Gut metabolites–immune system crosstalk in stroke. Immune 
system regulation by the gut microbiome after stroke. Lower panel: 
In the gut, stroke induces dysbiosis, mucosal barrier dysfunction, 
an increase of gut permeability, bacteria translocation, post-stroke 
infection, and a pro-inflammatory T-cell response via dendritic cells 
(DC). Immune cells, especially T-cells, CD64 + macrophages and 
DCs migrate from the gut to the meninges and the brain after stroke. 
The role of gut metabolites (AHR, secondary bile acids, MAMPs) 
as immunomodulators of intestinal immune cells is not well defined 
yet. Microbiota-derived SCFA are decreased after stroke and possi-
bly trigger an imbalance of γδT-IL-17 + cells and regulatory T-cells 
(Treg). Top panel: Supplementation of SCFA modulates neuronal 
activity and synapse density, and is associated with a decrease in 
microglia activation and an increase in Tregs together with a better 
recovery after stroke. Created with BioRender.com
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supplementation in mice prior to stroke improved behav-
ioral recovery, modified cortical network connectivity, and 
changed histological markers of synaptic plasticity, which 
was associated with improved long-term stroke outcomes. 
These effects were correlated with modification of micro-
glial morphology towards a homeostatic-like state and a 
reduction in brain-invading lymphocytes (Sadler et al. 2020). 
In another study, they observed that oral gavage of SCFA-
producing bacteria and inulin, a bacterial substrate for SCFA 
production, diminished neurological deficits and improved 
depressive-like behaviors following stroke in aged mice in 
comparison to young mice. Moreover, these changes were 
accompanied with a reduced percentage of IL-17 + γδT cells 
in the ischemic brain (Lee et al. 2020), but whether SCFAs 
directly influence T-cell polarization, and migration was not 
addressed. Surprisingly, the volume of the infarct was not 
affected by SCFA interventions in both studies. All these 
evidences indicate that the microbial metabolite SCFAs 
play an important role in post-stroke recovery and may be 
involved in the immunomodulatory role exerted by the gut 
microbiota after stroke (Fig. 1).
Conclusion
Here, we summarized the current findings on how the micro-
biota composition affects stroke outcome by modulating the 
immune response. The changes in gut microbiota following 
ischemic injury induces a predominantly pro-inflammatory 
T-cell response which is associated with greater infarct vol-
ume and worsened outcome. Because the gut microbiota 
is a very complex ecosystem, influenced by the environ-
ment and the host, with redundant functions and synergic 
relationships, identifying the functional microbial signature 
responsible for the neuroprotective effect could be a better 
approach rather than identifying specific bacterial species. 
Especially, since the composition of the gut microbiota sub-
stantially differs at deeper taxonomic level between humans 
and mice, it would be a better strategy to investigate the 
microbiome metabolomic profile for experimental research 
to be translated into clinics. However, to the best of our 
knowledge, there are no experimental data yet linking cau-
sality between specific microbiota-synthesized compounds 
and immune responses following brain damage. Further 
work addressing the molecular players involved in the cross-
talk between commensal bacteria and the immune system 
after stroke would be necessary for successfully applying 
these findings in stroke patients.
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